Our Culture
Our Mission
Better Medicine from Good Sciences, Improving Patients' Quality of Life
Our Vision
Pioneering Oral Delivery, Transforming Patients' Lives
Our Value
Science-driven, Long-term Perspective, Open-minded, and Pragmatic
ABOUT US
Oral Macromolecule Explorer
GDB is dedicated to developing oral delivery solutions for macromolecule drugs, following the Category 2 New Drug pathway in China and the 505(b)(2) regulatory pathway in the U.S.
GDB's innovative and globally patented oral delivery platform, MO-PION, enables the effective delivery of a wide range of large molecules. Its broad applicability has been demonstrated with diverse therapeutics, including nine incretin peptides (such as semaglutide), large polysaccharides (like heparin), and cyclic peptides (for example, micafungin).
TECHNOLOGY PLATFORM
MO-PION: The Macromolecule Oral Delivery Platform with GDB Global IP
WHY CHOOSE US？
GDB spends several years to develop mutual oral macromolecule technology and screening platform using beagle dogs
SHX-021, a first weekly oral semaglutide tablet
3~5 fold higher
VS reference drug
60~80% Variability
in Beagle dog model
3 months Stable
under accerated condition